← All trials
NCT03041766
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2016
- Primary completion
- Apr 6, 2017
- Completion date
- Jul 30, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- Immune DesignCollaborator
- Biomedical Research Center ESPOIR POUR LA SANTEOverall official - principal investigator
- Biomedical Research Center ESPOIR POUR LA SANTEStudy director
- Orygen Biotecnologia SACollaborator
- Biomedical Research Center EPLSCollaborator
- Oswaldo Cruz FoundationReponsible party - principal investigator
- Oswaldo Cruz FoundationStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.